

Special Issue

Evolution of Antimicrobial Resistance and Implications for Therapy in Respiratory Infections

Message from the Guest Editor

Respiratory infections in humans, caused by viruses, bacteria and fungi, are amongst the most common burdens on human health, in both the community and healthcare settings. Viral pandemics such as *Influenzae* A (H1N1pdm09) and the recent SARS-CoV-2 have amplified outbreaks of MDR bacterial cross-infections within facilities across the globe. MDR and pan-drug-resistant *Pseudomonas aeruginosa*, Carbapenem-resistant *Acinetobacter baumannii*, carbapenemase-producing Enterobacterales (CPE), MRSA, as well as resistant fungi such as *Candida auris* and *Aspergillus* spp, are now commonly seen and pose great danger to human lives in intensive care units. This Special Issue of *Antibiotics* invites researchers to submit work on the evolution and development of AMR among respiratory pathogens acquired in the community or in healthcare facilities, the epidemiology of acquired and inherent AMR among respiratory pathogens, as well new diagnostic tools and therapy implications designed to confront it, including the use of existing and new antimicrobial drugs.

Guest Editor

Dr. Regev Cohen

1. Infectious Diseases and Infection Control Units, Hillel-Yaffe Medical Center, Hadera, Israel
2. The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

Deadline for manuscript submissions

closed (31 July 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/161391

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)